Cochrane COVID-19 Study Register

A Phase 1/2 Open Label, Multicenter, Single Arm Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Single Dose Kamada Anti-SARS-CoV-2 in COVID-19 Hospitalized Patients With Pneumonia

  1. Study Type
  2. Interventional
  1. Study Aim
  2. Treatment and Management
  1. Study Design
  2. Single Arm/Controlled Before After
  1. Intervention Assignment
  2. Not Applicable

Safety, PK and PD of Kamada Anti-SARS-CoV-2 in COVID-19

Kamada, Ltd.
Trial registry record
No Results
Evaluate the safety pharmacokinetics and pharmacodynamics (PK/PD)of a single dose of Kamada anti-severe acute respiratory syndrome (SARS)- CoV-2 in patients hospitalized with COVID-19 caused pneumonia